Literature DB >> 17473499

Relapsing Campylobacter coli bacteremia with reactive arthritis in a patient with X-linked agammaglobulinemia.

Ayako Arai1, Asako Kitano, Etsuko Sawabe, Hirokazu Kanegane, Toshio Miyawaki, Osamu Miura.   

Abstract

A patient genetically diagnosed with X-linked agammaglobulinemia repeatedly developed bacteremia due to Campylobacter coli (C. coli) for one year and seven months in spite of immunoglobulin replacement therapy. Throughout the clinical course, C. coli with identical genetic patterns was repeatedly isolated from both blood and stool cultures, thus indicating that the patient had latent intestinal infection. The bacteremia was always accompanied by reactive arthritis. Since the immunoglobulin level was extremely low with severe B cell deficiency, the reactive arthritis must have been induced in a humoral immunity-independent manner. Adding oral minocycline following intravenous meropenem was very effective; the stool cultures became negative and the patient has been well for more than one year without relapse of bacteremia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17473499     DOI: 10.2169/internalmedicine.46.6108

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  9 in total

1.  First Case Report of Campylobacter volucris Bacteremia in an Immunocompromised Patient.

Authors:  Oh Joo Kweon; Yong Kwan Lim; Byeongpil Yoo; Hye Ryoun Kim; Tae-Hyoung Kim; Mi-Kyung Lee
Journal:  J Clin Microbiol       Date:  2015-04-01       Impact factor: 5.948

2.  Campylobacter jejuni cellulitis in a patient with pan-hypogammaglobulinaemia.

Authors:  S Hopkins; M Abuzakouk; E Brannigan; C Bergin; C Feighery
Journal:  BMJ Case Rep       Date:  2011-02-02

3.  Campylobacter infection in 4 patients treated with ibrutinib.

Authors:  Boris Sorin; Julien Vigneron; Jehane Fadlallah; Johanna Mondesir; Claire Fieschi; Eric Oksenhendler; Lionel Galicier; Marion Malphettes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-03-18       Impact factor: 3.267

Review 4.  Successful approach to treatment of Helicobacter bilis infection in X-linked agammaglobulinemia.

Authors:  Stuart E Turvey; Sara H Leo; Annette Boos; Gregory D Deans; Julie Prendiville; Richard I Crawford; Christof Senger; Mary Ellen Conley; Peter Tilley; Anne Junker; Loretta Janz; Robert Azana; Linda Hoang; Tracy L Morton
Journal:  J Clin Immunol       Date:  2012-07-28       Impact factor: 8.317

5.  Comparison of disk diffusion and agar dilution methods for erythromycin, ciprofloxacin, and tetracycline susceptibility testing of Campylobacter coli and for tetracycline susceptibility testing of Campylobacter jejuni subsp. jejuni.

Authors:  Christiane Gaudreau; Yves Girouard; Huguette Gilbert; Josée Gagnon; Sadjia Bekal
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

6.  Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.

Authors:  Mirva Lehtopolku; Ulla-Maija Nakari; Pirkko Kotilainen; Pentti Huovinen; Anja Siitonen; Antti J Hakanen
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

7.  Campylobacter jejuni Bacteremia in a Liver Cirrhosis Patient and Review of Literature: A Case Study.

Authors:  Jin Gu Yoon; Saem Na Lee; Hak Jun Hyun; Min Joo Choi; Ji Ho Jeon; Eunju Jung; Seonghui Kang; Jeeyong Kim; Ji Yun Noh; Won Suk Choi; Joon Young Song; Hee Jin Cheong; Woo Joo Kim
Journal:  Infect Chemother       Date:  2017-05-26

8.  Emergence of Carbapenem Non-susceptible Campylobacter coli after Long-term Treatment against Recurrent Bacteremia in a Patient with X-linked Agammaglobulinemia.

Authors:  Hideharu Hagiya; Keigo Kimura; Isao Nishi; Hisao Yoshida; Norihisa Yamamoto; Yukihiro Akeda; Kazunori Tomono
Journal:  Intern Med       Date:  2018-02-28       Impact factor: 1.271

Review 9.  Humoral immunodeficiencies: conferred risk of infections and benefits of immunoglobulin replacement therapy.

Authors:  Yael Gernez; Mary Grace Baker; Paul J Maglione
Journal:  Transfusion       Date:  2018-12       Impact factor: 3.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.